ATTR-CM: Earlier Diagnosis Reshapes Treatment Expectations

Clinical trials in transthyretin-mediated amyloid cardiomyopathyexternal link, opens in a new tab (ATTR-CM) are becoming harder to interpret for an encouraging reason: Patients are being identified earlier, entering studies with less advanced disease, and deteriorating more slowly.

This shift is changing how therapeutic benefit is defined. Although marked reductions in mortality and hospitalization remain important benchmarks, proving these differences has become harder because modern control groups are healthier than historical cohorts. Consequently, preserving walking capacity, cardiac function, and quality of life may offer more meaningful clinical insight than standard treatment–placebo margins indicate.